183 related articles for article (PubMed ID: 36907614)
1. Emerging Therapies in β-Thalassemia.
Bou-Fakhredin R; Kuo KHM; Taher AT
Hematol Oncol Clin North Am; 2023 Apr; 37(2):449-462. PubMed ID: 36907614
[TBL] [Abstract][Full Text] [Related]
2. Emerging therapies in β-thalassemia: toward a new era in management.
Bou-Fakhredin R; Tabbikha R; Daadaa H; Taher AT
Expert Opin Emerg Drugs; 2020 Jun; 25(2):113-122. PubMed ID: 32249632
[TBL] [Abstract][Full Text] [Related]
3. Beta Thalassemia: New Therapeutic Options Beyond Transfusion and Iron Chelation.
Motta I; Bou-Fakhredin R; Taher AT; Cappellini MD
Drugs; 2020 Jul; 80(11):1053-1063. PubMed ID: 32557398
[TBL] [Abstract][Full Text] [Related]
4. New therapeutic targets in transfusion-dependent and -independent thalassemia.
Cappellini MD; Motta I
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
[TBL] [Abstract][Full Text] [Related]
5. Beta Thalassemia: Monitoring and New Treatment Approaches.
Khandros E; Kwiatkowski JL
Hematol Oncol Clin North Am; 2019 Jun; 33(3):339-353. PubMed ID: 31030806
[TBL] [Abstract][Full Text] [Related]
6. Αlpha-thalassemia: A practical overview.
Musallam KM; Cappellini MD; Coates TD; Kuo KHM; Al-Samkari H; Sheth S; Viprakasit V; Taher AT
Blood Rev; 2024 Mar; 64():101165. PubMed ID: 38182489
[TBL] [Abstract][Full Text] [Related]
7. 2021 update on clinical trials in β-thalassemia.
Musallam KM; Bou-Fakhredin R; Cappellini MD; Taher AT
Am J Hematol; 2021 Nov; 96(11):1518-1531. PubMed ID: 34347889
[TBL] [Abstract][Full Text] [Related]
8. Unmet needs in β-thalassemia and the evolving treatment landscape.
Njeim R; Naouss B; Bou-Fakhredin R; Haddad A; Taher A
Transfus Clin Biol; 2024 Feb; 31(1):48-55. PubMed ID: 38128605
[TBL] [Abstract][Full Text] [Related]
9. Recent trends in treatment of thalassemia.
El-Beshlawy A; El-Ghamrawy M
Blood Cells Mol Dis; 2019 May; 76():53-58. PubMed ID: 30792169
[TBL] [Abstract][Full Text] [Related]
10. New Insights Into Pathophysiology of β-Thalassemia.
Sanchez-Villalobos M; Blanquer M; Moraleda JM; Salido EJ; Perez-Oliva AB
Front Med (Lausanne); 2022; 9():880752. PubMed ID: 35492364
[TBL] [Abstract][Full Text] [Related]
11. Novel therapies in β-thalassaemia.
Grech L; Borg K; Borg J
Br J Clin Pharmacol; 2022 Jun; 88(6):2509-2524. PubMed ID: 34004015
[TBL] [Abstract][Full Text] [Related]
12. Iron metabolism and ineffective erythropoiesis in beta-thalassemia mouse models.
Ramos P; Melchiori L; Gardenghi S; Van-Roijen N; Grady RW; Ginzburg Y; Rivella S
Ann N Y Acad Sci; 2010 Aug; 1202():24-30. PubMed ID: 20712768
[TBL] [Abstract][Full Text] [Related]
13. β-Thalassemia intermedia: a comprehensive overview and novel approaches.
Asadov C; Alimirzoeva Z; Mammadova T; Aliyeva G; Gafarova S; Mammadov J
Int J Hematol; 2018 Jul; 108(1):5-21. PubMed ID: 29380178
[TBL] [Abstract][Full Text] [Related]
14. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.
Ginzburg Y; Rivella S
Blood; 2011 Oct; 118(16):4321-30. PubMed ID: 21768301
[TBL] [Abstract][Full Text] [Related]
15. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia.
Schmidt PJ; Toudjarska I; Sendamarai AK; Racie T; Milstein S; Bettencourt BR; Hettinger J; Bumcrot D; Fleming MD
Blood; 2013 Feb; 121(7):1200-8. PubMed ID: 23223430
[TBL] [Abstract][Full Text] [Related]
16. A moderate transfusion regimen may reduce iron loading in beta-thalassemia major without producing excessive expansion of erythropoiesis.
Cazzola M; Borgna-Pignatti C; Locatelli F; Ponchio L; Beguin Y; De Stefano P
Transfusion; 1997 Feb; 37(2):135-40. PubMed ID: 9051086
[TBL] [Abstract][Full Text] [Related]
17. Iron overload in β-thalassemia intermedia: an emerging concern.
Musallam KM; Cappellini MD; Taher AT
Curr Opin Hematol; 2013 May; 20(3):187-92. PubMed ID: 23426199
[TBL] [Abstract][Full Text] [Related]
18. Erythropoiesis in lower-risk myelodysplastic syndromes and beta-thalassemia.
Cappellini MD; Taher AT; Verma A; Shah F; Hermine O
Blood Rev; 2023 May; 59():101039. PubMed ID: 36577601
[TBL] [Abstract][Full Text] [Related]
19. Beta-thalassemia: renal complications and mechanisms: a narrative review.
Demosthenous C; Vlachaki E; Apostolou C; Eleftheriou P; Kotsiafti A; Vetsiou E; Mandala E; Perifanis V; Sarafidis P
Hematology; 2019 Dec; 24(1):426-438. PubMed ID: 30947625
[TBL] [Abstract][Full Text] [Related]
20. Oral ferroportin inhibitor vamifeport for improving iron homeostasis and erythropoiesis in β-thalassemia: current evidence and future clinical development.
Porter J; Taher A; Viprakasit V; Kattamis A; Coates TD; Garbowski M; Dürrenberger F; Manolova V; Richard F; Cappellini MD
Expert Rev Hematol; 2021 Jul; 14(7):633-644. PubMed ID: 34324404
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
